Quantum-Si (NASDAQ:QSI) Given New $1.50 Price Target at Canaccord Genuity Group

Quantum-Si (NASDAQ:QSI) had its target price lowered by analysts at Canaccord Genuity Group from $2.00 to $1.50 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a “hold” rating on the stock. Canaccord Genuity Group’s target price suggests a potential upside of 18.11% from the company’s previous close.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Quantum-Si in a report on Monday, December 8th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $3.60.

Quantum-Si Price Performance

Quantum-Si stock opened at $1.27 on Monday. Quantum-Si has a one year low of $0.95 and a one year high of $5.77. The company’s fifty day moving average price is $1.67 and its two-hundred day moving average price is $1.58. The company has a market capitalization of $273.67 million, a price-to-earnings ratio of -1.90 and a beta of 2.96.

Quantum-Si (NASDAQ:QSI) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.17) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.17). The company had revenue of $0.55 million during the quarter, compared to analysts’ expectations of $0.60 million. Quantum-Si had a negative return on equity of 47.90% and a negative net margin of 3,677.97%. As a group, sell-side analysts anticipate that Quantum-Si will post -0.65 earnings per share for the current year.

Insider Buying and Selling at Quantum-Si

In related news, Director Jonathan M. Rothberg sold 26,095 shares of the stock in a transaction that occurred on Thursday, October 16th. The stock was sold at an average price of $3.07, for a total transaction of $80,111.65. Following the completion of the sale, the director owned 1,904,866 shares in the company, valued at $5,847,938.62. This represents a 1.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 22.95% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Wealth Management Associates Inc. lifted its holdings in shares of Quantum-Si by 14.8% during the 3rd quarter. Wealth Management Associates Inc. now owns 30,950 shares of the company’s stock worth $44,000 after acquiring an additional 4,000 shares during the period. SBI Securities Co. Ltd. raised its position in Quantum-Si by 28.6% in the third quarter. SBI Securities Co. Ltd. now owns 33,616 shares of the company’s stock worth $47,000 after purchasing an additional 7,475 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Quantum-Si by 15.6% during the second quarter. JPMorgan Chase & Co. now owns 66,656 shares of the company’s stock worth $131,000 after purchasing an additional 9,005 shares during the period. Corebridge Financial Inc. boosted its holdings in Quantum-Si by 18.2% during the first quarter. Corebridge Financial Inc. now owns 58,876 shares of the company’s stock valued at $71,000 after purchasing an additional 9,086 shares in the last quarter. Finally, Wolverine Asset Management LLC grew its stake in shares of Quantum-Si by 140.0% in the 2nd quarter. Wolverine Asset Management LLC now owns 16,501 shares of the company’s stock valued at $32,000 after purchasing an additional 9,626 shares during the period. 39.90% of the stock is currently owned by institutional investors and hedge funds.

About Quantum-Si

Quantum-Si Inc is a life sciences instrumentation company headquartered in Guilford, Connecticut, developing next-generation proteomics solutions based on semiconductor sequencing technology. The company’s core offering centers on a proprietary single-molecule protein sequencing platform that uses a silicon-based sensor chip to convert protein data into digital signals. This approach is designed to deliver high sensitivity, single-amino-acid resolution and deep proteome coverage while potentially reducing cost and complexity compared to traditional mass spectrometry methods.

Quantum-Si’s product roadmap includes the development and commercialization of an integrated system comprising instruments, consumable reagents and proprietary data analysis software.